Exploratory aims Exploratory aims are to evaluate the change from baseline that treatment with 400 mg oral SAMe for 180 days has, compared to placebo, on 1) blood total tau, amyloid-, and neurofilament light levels, and 2) cognitive status as assessed by the Standardized MiniMental State Examination, Cognitive Dementia Rating, California Verbal Learning Test 3rd Edition, Montreal Cognitive Assessment, and Digit Symbol Substitution Test
Abbasi N R, Shaw H M, Rigel D S et al
10.1542/peds.2020-029074 106
Semaglutide (Ozempic for diabetes, Wegovy for weight loss) is a single GLP-1 receptor agonist
Novo Nordisk is the same company that manufactures Ozempic and Wegovy
Its full name is glutamyl-cysteinyl-glycine, and its English name is glutamyl-cysteinylglycine, or glutathione for short